Clinical trials: Lipoprotein Disorder
Cardiovascular Disease
Effects of Niacin Therapy on Lipoprotein Composition and Function
Background: Niacin is a vitamin in many foods, including meats, fish, fruits, and vegetables. It is often used as a dietary supplement that causes many improvements in the body. Researchers think it can affect heart health.
- Trial name
- NCT02322203
- Testing
- Niacin Extended Release
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypercholesterolemia
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that…
- Trial name
- ACT II (NCT01381679)
- Testing
- Ezetimibe
- Volunteers
- 1,682 people
- Sponsor
- Organon and Co
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides
The primary purpose of this study is to test the effect and safety of three different doses of ABT-143 compared to simvastatin in subjects with elevated levels of low density lipoprotein cholesterol ("bad cholesterol") and…
- Trial name
- NCT00812955
- Testing
- ABT-143, simvastatin
- Where
- 129 sites in United States
- Volunteers
- 474 people
- Sponsor
- AstraZeneca
Dyslipidemia
The Effect of 3-Week Consumption of Soya Beverage Enriched With Plant Sterols on Serum LDL-C
This is a local, single-center, two-arm, randomized, double-blind, placebo-controlled clinical trial that examines the LDL-C-lowering effect of the consumption of a soya beverage enriched with plant sterol for 3 weeks.
- Trial name
- NCT02881658
- Testing
- Plant sterols-enriched soya beverage provided by Vitasoy, Soya beverage provided by Vitasoy
- Where
- Hong Kong
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Rheumatoid Arthritis
Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis
The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).
- Trial name
- NCT01262118
- Testing
- CP-690,550 (tasocitinib)
- Where
- 11 sites in United States, Hungary
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Pfizer
Elevated Lipoprotein(a), Cardiovascular Disease
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Trial name
- NCT03070782
- Testing
- ISIS 681257
- Where
- 32 sites in United States, Canada and 3 more
- Volunteers
- 286 people
- Sponsor
- Akcea Therapeutics
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) [Lp(a)].
- Trial name
- NCT03626662
- Testing
- AMG 890
- Where
- 9 sites in United States, Australia
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Amgen
Overweight; Hyperlipidemia
Efficacy and Safety of Fermented Barley on Decrement of Body Fat in Obese Subjects
Barley, like oats, is a rich source of the soluble fibre β-glucan, which has been shown to significantly lower LDL-cholesterol (LDL-C). However, barley foods have been less widely studied.
- Trial name
- NCT01402128
- Testing
- Barley beta-glucan(3.0g)
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Lipid Disorder, Triglycerides High
Vascepa to Accelerate Lipoprotein Uptake and Elimination
This study is a Phase 1 pilot/feasibility mechanistic experiment to help clarify the mechanism of action of an EPA-rich fish oil preparation, icosapent ethyl, on lipid changes in statin-treated patients with residual…
- Conditions
- Lipid Disorder, Triglycerides High, Dyslipidemias
- Trial name
- VALUE (NCT03885661)
- Testing
- Icosapent Ethyl 1000 MG [Vascepa]
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Hypertriglyceridemia
Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia
The objectives of this study are to assess the effects of 4 g/d prescription omega-3 acid ethyl esters (POM3), compared with a placebo, on indices of insulin sensitivity and secretion, as well as aspects of the fasting and…
- Trial name
- NCT01034540
- Testing
- POM3
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Provident Clinical Research
Familial Hypercholesterolemia
Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy
The objectives of this post-surveillance study are to continue to evaluate the safety and effectiveness of the H.E.L.P. System. The safety and effectiveness will be assessed by evaluating the occurrence of death, cardiovascular…
- Trial name
- Secura (NCT00916643)
- Testing
- HELP Secura (apheresis treatment)
- Volunteers
- 113 people
- Sponsor
- B. Braun Medical Inc.
Subjects With Hyperlipidemia, Dyslipidemia
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
- Trial name
- ANITSCHKOW (NCT02729025)
- Testing
- Evolocumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Metabolic Syndrome
Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids
The objective of this study is to provide critical information regarding both common and distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.
- Trial name
- NCT02670382
- Testing
- EPA, DHA, sunflower oil
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tufts University
Heterozygous Familial Hypercholesterolemia
Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.
- Trial name
- HAUSER-RCT (NCT02392559)
- Testing
- Evolocumab
- Where
- 66 sites in United States, Australia and 24 more
- Volunteers
- 158 people
- Sponsor
- Amgen
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Type 2 Diabetes Mellitus
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes
Metabolic defects contributing to the development of type 2 diabetes (T2D) are relative insulin insufficiency and insulin resistance that are associated with a cluster of abnormalities that increase the risk for cardiovascular…
- Trial name
- NCT01156597
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Type 2 Diabetes, African American
Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes
Compared to other races, African-Americans with type 2 diabetes have different cholesterol levels, specifically triglycerides and low density lipoprotein.
- Conditions
- Type 2 Diabetes, African American, Cholesterol, Lipoprotein
- Trial name
- LAAD (NCT01494298)
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- Mercer University
Homozygous Familial Hypercholesterolemia (HoFH)
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
This first-in-human study is intended to evaluate the safety and preliminary effectiveness of AAV (Adeno-associated virus)-based liver-directed gene therapy in the treatment of adults with Homozygous Familial Hypercholesterolemia…
- Trial name
- NCT02651675
- Testing
- AAV directed hLDLR gene therapy
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 9 people
- Sponsor
- REGENXBIO Inc.
Hypercholesterolemia
Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
The purpose of this study is to compare the efficacy of a Vytorin 10/80 tablet, an approved agent for the treatment of elevated LDL cholesterol which combines the cholesterol absorption inhibitor Ezetimibe 10 mg and simvastatin…
- Trial name
- NCT00762164
- Testing
- Vytorin, Simvastatin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bronx VA Medical Center
Lipoprotein Disorder
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
- Trial name
- KRAKEN (NCT05563246)
- Testing
- LY3473329
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company